上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi Biologics Successfully Completed First FDA Routine GMP Inspection 2019-04-17 09:14
WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs 2019-04-16 20:00
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership 2019-04-09 08:36
WuXi Biologics Wins 2019 CMO Leadership Awards in All Six Core Categories 2019-04-03 20:06
WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC 2019-03-26 08:24
WuXi Biologics Receives EMA GMP Certificates 2019-03-20 08:07
WuXi Biologics Continues to Deliver Record Results 2019-03-18 22:25
WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA 2019-02-28 09:52
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million 2019-02-26 08:23
EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo (TM) at WuXi Biologics 2019-02-19 14:21
EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics 2019-02-19 08:21
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership 2019-02-12 08:04
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership 2018-12-19 20:16
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development 2018-12-13 07:30
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity 2018-12-12 08:08
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million 2018-12-11 15:00
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million 2018-12-11 09:47
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics 2018-12-10 10:21
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market" 2018-12-06 18:20
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market" 2018-12-06 18:12
1 4 5 6 7 8